Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis
Tumoral necrosis factor α plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/286857 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850235349008121856 |
|---|---|
| author | Daniel Sánchez-Cano José Luis Callejas-Rubio Ricardo Ruiz-Villaverde Raquel Ríos-Fernández Norberto Ortego-Centeno |
| author_facet | Daniel Sánchez-Cano José Luis Callejas-Rubio Ricardo Ruiz-Villaverde Raquel Ríos-Fernández Norberto Ortego-Centeno |
| author_sort | Daniel Sánchez-Cano |
| collection | DOAJ |
| description | Tumoral necrosis factor α plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a variety of disorders, such as rheumatoid arthritis, spondyloarthropatties, inflammatory bowel disease, and psoriasis. Nonetheless, theoretically, some other autoimmune disorders may benefit from these agents. Our aim is to review these off-label uses of anti-TNF blockers in three common conditions: Behçet’s disease, sarcoidosis, and noninfectious uveitis. Due to the insufficient number of adequate clinical trials and consequently to their lower prevalence compared to other immune disorders, this review is mainly based on case reports and case series. |
| format | Article |
| id | doaj-art-10cdc6fd9e7a4d4dba19e39bdb295358 |
| institution | OA Journals |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-10cdc6fd9e7a4d4dba19e39bdb2953582025-08-20T02:02:17ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/286857286857Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious UveitisDaniel Sánchez-Cano0José Luis Callejas-Rubio1Ricardo Ruiz-Villaverde2Raquel Ríos-Fernández3Norberto Ortego-Centeno4Internal Medicine Department, Hospital Santa Ana, 18600 Motril, SpainUnidad de Enfermedades Autoinmunes Sistémicas, Hospital Universitario San Cecilio, 18012 Granada, SpainDermatology Department, Complejo Hospitalario Ciudad de Jaén, 23001 Jaén, SpainUnidad de Enfermedades Autoinmunes Sistémicas, Hospital Universitario San Cecilio, 18012 Granada, SpainUnidad de Enfermedades Autoinmunes Sistémicas, Hospital Universitario San Cecilio, 18012 Granada, SpainTumoral necrosis factor α plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a variety of disorders, such as rheumatoid arthritis, spondyloarthropatties, inflammatory bowel disease, and psoriasis. Nonetheless, theoretically, some other autoimmune disorders may benefit from these agents. Our aim is to review these off-label uses of anti-TNF blockers in three common conditions: Behçet’s disease, sarcoidosis, and noninfectious uveitis. Due to the insufficient number of adequate clinical trials and consequently to their lower prevalence compared to other immune disorders, this review is mainly based on case reports and case series.http://dx.doi.org/10.1155/2013/286857 |
| spellingShingle | Daniel Sánchez-Cano José Luis Callejas-Rubio Ricardo Ruiz-Villaverde Raquel Ríos-Fernández Norberto Ortego-Centeno Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis Mediators of Inflammation |
| title | Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis |
| title_full | Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis |
| title_fullStr | Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis |
| title_full_unstemmed | Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis |
| title_short | Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis |
| title_sort | off label uses of anti tnf therapy in three frequent disorders behcet s disease sarcoidosis and noninfectious uveitis |
| url | http://dx.doi.org/10.1155/2013/286857 |
| work_keys_str_mv | AT danielsanchezcano offlabelusesofantitnftherapyinthreefrequentdisordersbehcetsdiseasesarcoidosisandnoninfectiousuveitis AT joseluiscallejasrubio offlabelusesofantitnftherapyinthreefrequentdisordersbehcetsdiseasesarcoidosisandnoninfectiousuveitis AT ricardoruizvillaverde offlabelusesofantitnftherapyinthreefrequentdisordersbehcetsdiseasesarcoidosisandnoninfectiousuveitis AT raquelriosfernandez offlabelusesofantitnftherapyinthreefrequentdisordersbehcetsdiseasesarcoidosisandnoninfectiousuveitis AT norbertoortegocenteno offlabelusesofantitnftherapyinthreefrequentdisordersbehcetsdiseasesarcoidosisandnoninfectiousuveitis |